Research overview
KPV: what the research shows
What is KPV?
KPV is a synthetic tripeptide made of lysine, proline, and valine. It reproduces the last three residues (positions 11 to 13) of alpha-melanocyte-stimulating hormone, or alpha-MSH, a 13-residue peptide with the sequence SYSMEHFRWGKPV [1] [2]. PubChem lists KPV under the names alpha-MSH (11-13) and ACTH-(11-13), since the same three residues also occur in adrenocorticotropic hormone [1].
Alpha-MSH is derived from proopiomelanocortin and has been widely studied for anti-inflammatory and protective effects. A 2008 review explained that one obstacle to studying alpha-MSH in inflammation models is its pigmentary activity, and that KPV attracted interest because it retained anti-inflammatory activity in experimental systems without that pigmentary action [3].
Most published KPV research is cell and rodent work on inflammatory signaling, the intestinal lining, and microbial growth. It is far less studied than larger research peptides, and the bulk of the work comes from a limited number of research groups.
| Sequence | Lys-Pro-Val (KPV) |
|---|---|
| Length | 3 amino acids (tripeptide) |
| Origin | C-terminal residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH) |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.43 g/mol |
| CAS number | 67727-97-3 |
| PubChem CID | 125672 |
| Other names | alpha-MSH (11-13), ACTH-(11-13), L-lysyl-L-prolyl-L-valine (PubChem synonyms) |
Mechanisms studied
Several mechanisms have been proposed to explain the effects reported in experimental models. None has been confirmed in humans, and the studies below do not all agree on how KPV acts.
Uptake through the PepT1 transporter
PepT1 is a di- and tripeptide transporter normally found in the small intestine and induced in the colon during inflammation. In a 2008 study using human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and human Jurkat T cells, KPV was transported into cells by PepT1. At nanomolar concentrations it inhibited activation of NF-kappaB and MAP kinase inflammatory pathways and reduced secretion of pro-inflammatory cytokines after cytokine stimulation [4].
NF-kappaB nuclear import
A 2012 study in immortalized human bronchial epithelial cells (16HBE14o-) reported that KPV inhibited TNF-alpha and virus-induced NF-kappaB signaling and reduced secretion of the chemokines IL-8 and eotaxin. The effect was associated with nuclear import of KPV, stabilization of the inhibitor IkappaB-alpha, and reduced nuclear translocation of the p65 RelA subunit. Competition assays suggested KPV interacted with the importin-alpha3 binding site on p65 [5].
Melanocortin receptor signaling
Whether KPV acts through melanocortin receptors is unsettled. In a 2004 study of human keratinocytes, alpha-MSH, KPV, and related peptides did not raise cyclic AMP, but triggered intracellular calcium signals under specific conditions. In Chinese hamster ovary cells engineered to express the melanocortin-1 receptor (MC1R), KPV raised intracellular calcium [6]. In a mouse colitis study, KPV remained active in mice with a non-functional MC1R, which the authors interpreted as evidence of at least partly MC1R-independent action [7].
Direct antimicrobial activity
In a 2000 study, alpha-MSH and KPV inhibited colony formation of Staphylococcus aureus and reduced viability and germ-tube formation of Candida albicans in vitro, over a broad range of concentrations. The authors linked the effect partly to increased cyclic AMP in the microbes [2]. A 2011 study reported that alpha-MSH (11-13) killed more than 90% of methicillin-sensitive and methicillin-resistant S. aureus cells at micromolar concentrations, depolarizing and permeabilizing bacterial membranes in a manner similar to the full-length hormone [8].
Areas of research
Intestinal inflammation models
Colitis models are the most developed area of KPV research. In the 2008 PepT1 study, KPV given in drinking water reduced the incidence of colitis induced by dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) in mice, with lower pro-inflammatory cytokine expression [4]. A second 2008 study reported that KPV reduced inflammatory infiltrates and myeloperoxidase activity in DSS colitis and in a T-cell transfer colitis model in mice [7].
Later work focused on delivery systems in rodent models. A 2017 study loaded KPV into hyaluronic-acid-functionalized nanoparticles and reported targeted uptake into colonic epithelial cells and macrophages, with reduced mucosal damage and TNF-alpha in a mouse ulcerative colitis model [9]. A 2023 review placed these findings within broader preclinical research on the melanocortin system in inflammatory bowel conditions [10].
Colitis-associated tumor models
A 2016 mouse study examined the role of PepT1 in colitis-associated tumor formation. KPV reduced tumorigenesis in wild-type mice but had no such effect in mice lacking PepT1, consistent with the transporter-dependent mechanism described above [11].
Oral mucosa models
In a 2021 rat model of chemotherapy-induced oral mucositis, KPV was incorporated into a temperature-sensitive mucoadhesive hydrogel. The authors reported reduced IL-1beta and TNF-alpha, increased IL-10, improved tissue morphology, and antibacterial activity against S. aureus, including in MRSA-infected wounds [12].
Brain injury models
In a 2013 mouse model of traumatic brain injury, a single administration of alpha-MSH (11-13) was followed by a smaller secondary lesion volume, reduced microglial activation by morphology, and less neuronal apoptosis. Expression of the inflammatory markers TNF-alpha and IL-1beta was not reduced [13].
Related tripeptides
KPV is often discussed alongside KdPT, which the 2008 review described as a derivative of KPV corresponding to residues 193 to 195 of interleukin-1beta, and which was also emerging as an anti-inflammatory tripeptide in experimental systems [3]. The two are distinct compounds, and results for one should not be assumed for the other. The same review summarized how the parent hormone, alpha-MSH, affected NF-kappaB activation, adhesion molecule expression, cytokine production, and inflammatory cell migration across animal models of skin, gut, eye, lung, and joint inflammation, which is the background against which KPV research developed [3].
How to read this literature
Several features of the KPV literature limit how far its findings can be generalized. Many studies combined KPV with a delivery vehicle, such as nanoparticles or hydrogels, so the measured effects reflect the formulation as well as the peptide [9] [10] [12]. Inflammation models such as DSS and TNBS colitis differ from each other and from naturally occurring disease, and a substantial part of the intestinal work comes from a small number of laboratories [4] [10]. Concentrations tested in cell and microbial assays spanned a very wide range, from femtomolar to micromolar, and the mechanisms proposed in epithelial cells, keratinocytes, and microbes are not the same [4] [6] [9].
Open research questions
- Which receptor or transport pathways account for KPV activity in different cell types, given conflicting evidence on melanocortin receptor involvement [6] [7].
- Stability and handling of a very small, unmodified tripeptide in biological fluids, which has driven much of the delivery-system research [9].
- Whether findings from a few rodent model systems replicate across independent laboratories and larger animal models.
State of the human evidence
There is essentially no published human evidence for KPV. A PubMed search for KPV clinical or randomized trials on the review date returned no results, and FDA states that it has not identified any human exposure data on drug products containing KPV [14].
The findings summarized on this page come from cell lines, isolated microbes, and rodent models. They should not be read as evidence of safety or benefit in people, and KPV should be regarded as an investigational research compound.
Regulatory status
- Not FDA approved. KPV is an unapproved peptide. It is not approved by the U.S. Food and Drug Administration for any human use, and the compounding vote described below does not make it an approved drug [15].
- Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) includes KPV among substances whose nominations were withdrawn. FDA notes that it has not identified human exposure data for KPV products and lacks important information about safety issues [14].
- Advisory committee vote. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend KPV for the 503A bulks list, evaluated for wound healing and inflammatory conditions. FDA staff had recommended against adding the peptides reviewed. The vote is a non-binding recommendation, FDA is not bound by it, and FDA had not acted on it at the time of this review [15] [16] [17].
- Sport. KPV is not named individually on the World Anti-Doping Agency 2026 Prohibited List. The list's S0 class covers pharmacological substances with no current approval by any governmental health authority for human therapeutic use [18].
Rejuvatide supplies KPV strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
Every Rejuvatide lot of KPV is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin under USP <85>. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.
KPV is also a component of our Klow Blend, alongside BPC-157, TB-500, and GHK-Cu. Browse all research peptides in this category, or see our BPC-157 and TB-500 research pages.
Storage of lyophilized material
KPV ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.